Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EXTI - only public co. developing liver device -- Ignore unavailable to you. Want to Upgrade?

To: Shawn Donahue who wrote (235)	3/10/1998 12:58:00 AM
From: CENTrader	Read Replies (1) \| Respond to of 1063

Shawn, <<Here is another reason for the need of EXTI to quickly develop their proprietary liver dialysis machine!>> Exten has ALREADY developed the machine. The problem now is to aquire funds to prove that to the FDA. I give you the following reference... Exten Industries, Inc. (OTC: EXTI), through its Xenogenics subsidiary, has developed an artificial liver, SYBIOL (synthetic bio-liver), which will allow a patient to recover from liver disease or stay alive while waiting for a transplant. Currently, eight people die each day in the U.S. while waiting for a liver transplant. The company has patents pending on its technology and is working to obtain FDA approval for use of the SYBIOL device in the U.S. If they didn't ALREADY have a viable product, I would have my money invested elsewhere! Regards, Bill